De Priyanka, Kumar Vinay, Kar Supratik, Roy Kunal, Leszczynski Jerzy
Drug Theoretics and Cheminformatics Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata-700032, India.
Interdisciplinary Center for Nanotoxicity, Department of Chemistry, Physics and Atmospheric Sciences, Jackson State University, Jackson, MS 39217 USA.
Struct Chem. 2022;33(5):1741-1753. doi: 10.1007/s11224-022-01975-3. Epub 2022 Jun 7.
The worldwide burden of coronavirus disease 2019 (COVID-19) is still unremittingly prevailing, with more than 440 million infections and over 5.9 million deaths documented so far since the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic. The non-availability of treatment further aggravates the scenario, thereby demanding the exploration of pre-existing FDA-approved drugs for their effectiveness against COVID-19. The current research aims to identify potential anti-SARS-CoV-2 drugs using a computational approach and repurpose them if possible. In the present study, we have collected a set of 44 FDA-approved drugs of different classes from a previously published literature with their potential antiviral activity against COVID-19. We have employed both regression- and classification-based quantitative structure-activity relationship (QSAR) modeling to identify critical chemical features essential for anticoronaviral activity. Multiple models with the consensus algorithm were employed for the regression-based approach to improve the predictions. Additionally, we have employed a machine learning-based read-across approach using Read-Across-v3.1 available from https://sites.google.com/jadavpuruniversity.in/dtc-lab-software/home and linear discriminant analysis for the efficient prediction of potential drug candidate for COVID-19. Finally, the quantitative prediction ability of different modeling approaches was compared using the sum of ranking differences (SRD). Furthermore, we have predicted a true external set of 98 pharmaceuticals using the developed models for their probable anti-COVID activity and their prediction reliability was checked employing the "Prediction Reliability Indicator" tool available from https://dtclab.webs.com/software-tools. Though the present study does not target any protein of viral interaction, the modeling approaches developed can be helpful for identifying or screening potential anti-coronaviral drug candidates.
The online version contains supplementary material available at 10.1007/s11224-022-01975-3.
2019年冠状病毒病(COVID-19)的全球负担仍在持续肆虐,自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行以来,迄今已有超过4.4亿例感染病例和超过590万例死亡病例记录在案。治疗方法的缺乏进一步加剧了这种情况,因此需要探索美国食品药品监督管理局(FDA)先前批准的药物对COVID-19的有效性。当前的研究旨在使用计算方法识别潜在的抗SARS-CoV-2药物,并在可能的情况下对其进行重新利用。在本研究中,我们从先前发表的文献中收集了一组44种不同类别的FDA批准药物及其对COVID-19的潜在抗病毒活性。我们采用了基于回归和分类的定量构效关系(QSAR)模型来识别抗冠状病毒活性所必需的关键化学特征。基于回归的方法采用了具有共识算法的多个模型来改进预测。此外,我们使用了基于机器学习的类推方法,该方法使用可从https://sites.google.com/jadavpuruniversity.in/dtc-lab-software/home获得的Read-Across-v3.1以及线性判别分析来有效预测COVID-19的潜在候选药物。最后,使用排名差异总和(SRD)比较了不同建模方法的定量预测能力。此外,我们使用开发的模型预测了一组98种药物的真实外部集,以评估它们可能的抗COVID活性,并使用可从https://dtclab.webs.com/software-tools获得的“预测可靠性指标”工具检查了它们的预测可靠性。尽管本研究未针对任何病毒相互作用蛋白,但所开发的建模方法有助于识别或筛选潜在的抗冠状病毒候选药物。
在线版本包含可在10.1007/s11224-022-01975-3获取的补充材料。